CEO Emma Walmsley said the company has been anticipating tariffs on the industry and is “confident” the company can navigate through it, Ashleigh Furlong and Ruth David of Bloomberg reports. The U.S.

GSK CEO Emma Walmsley’s $13 million salary is predicated on picking the right people to steer cutting-edge drug development for the world’s most challenging diseases. During her eight years at ...

Walmsley says GSK is “incredibly intentional” in how the company recruits and trains talent. The company’s management has worked on ways to reduce their rate of misses when ...

The Trump administration's apparent vaccine skepticism and proposed tariffs on Pharma could significantly impact GSK plc's vaccine division and its overall profitability, despite CEO Walmsley's ...

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

As first quarter earnings begin, executives are confronting market turmoil, regulatory instability and the threat of U.S.

M4TB, through its participation in ERA4TB – a European Union’s Horizon 2020 research and innovation program – is supporting initial development of a long-acting injectable ...

Speculation is mounting GlaxoSmithKline's CEO Emma Walmsley may pay the price for the company’s lacklustre performance, after the dreaded activist investor Elliott Management built a stake in ...

ABL Bio has announced a global licensing agreement with GSK, allowing the latter to develop medicines for neurodegenerative ...

GlaxoSmithKline (GSK) appears to be focusing more on finding a new CEO than any large M&A deals after last year's $20 billion asset swap with Novartis, according to a briefing following strong Q1 ...